BCS Financial Launches Gene Therapy Stop Loss for Employer Groups
BCS Financial Launches Gene Therapy Stop Loss for Employer Groups
The product offers self-funded employer groups the option to "carve out" the gene therapy ingredient costs in a separate stop loss policy, providing protection against the therapy costs themselves, and reducing the risk of lasering and non-renewals on their traditional stop loss policy. The product is currently available for quoting in 45 states.New solution offers additional protection from gene therapy risk for self-funded employer groups
新解决方案为自费雇主团体提供额外的基因疗法风险保护
CHICAGO, Oct. 3, 2024 /PRNewswire/ -- BCS Financial today announces a new stop loss product for small to mid-sized self-funded employer groups seeking additional protection from gene therapy costs. Known as Stop Loss GTS, the product is designed to sit alongside traditional stop loss coverage and provide additional risk protection against unknown – and unprecedented – gene therapy costs.
芝加哥，2024年10月3日 / PRNewswire / - 今天，BCS Financial宣布推出一款新的停损产品，供寻求额外保护免受基因疗法成本影响的中小型自费雇主团体使用。该产品名为Stop Loss GTS，旨在与传统的停损保险一起运作，并为未知 - 以及前所未有的 - 基因疗法成本提供额外的风险保护。
"Gene therapies are changing modern medicine, and they are also changing the self-funded insurance market," said Mehb Khoja, BCS Head of Large Claims Solutions. "With treatments ranging $2M to $4M, it's going to be a challenge for many self-funded employer groups to finance these costs within their traditional stop loss policies. That's why we've created Stop Loss GTS – to help fill a gap in the market and provide additional protection for employers."
"基因疗法正在改变现代医学，也正在改变自费保险市场，" BCS大额索赔解决方案主管Mehb Khoja表示。"随着治疗费用介于200万到400万元之间，对许多自费雇主团体来说，在传统停损政策内筹措这些费用将是一个挑战。这就是我们创建Stop Loss GTS的原因 - 以帮助填补市场上的空白，并为雇主提供额外的保护。"
The product offers self-funded employer groups the option to "carve out" the gene therapy ingredient costs in a separate stop loss policy, providing protection against the therapy costs themselves, and reducing the risk of lasering and non-renewals on their traditional stop loss policy. The product is currently available for quoting in 45 states.
该产品为自费雇主团体提供了一个选项，即将基因疗法成本分拆为单独的停损保单，提供对疗法成本本身的保护，降低传统停损政策上的单一核算和不续保的风险。该产品目前可在45个州报价。
Stop Loss GTS is the latest addition to BCS's suite of solutions designed to provide additional protection for this growing risk.
Stop Loss GTS是BCS旨在为这一不断增长的风险提供额外保护的解决方案系列的最新补充。
"Our goal is to help alleviate the unexpected burden of these expenses for self-insured employers and health plans," said Khoja.
"我们的目标是帮助减轻这些意外费用对自保雇主和健康计划的负担，" Khoja说。
"We've had solutions in the market since 2019 when the first gene therapies were FDA approved, and have introduced new products as additional therapies have hit the market. As the gene therapy pipeline continues to grow, BCS will continue to develop new and innovative products and solutions alongside with it."
"自2019年第一种基因疗法获得FDA批准以来，我们就在市场上提供解决方案，并在其他疗法进入市场时推出新产品。随着基因疗法产品管线的持续增长，BCS将继续开发新的创新产品和方案。"
For more information about Stop Loss GTS, or other gene therapy insurance solutions, visit bcsf.com or contact your insurance broker.
了解更多有关止损GTS或其他基因疗法保险解决方案，请访问bcsf.com或联系您的保险经纪人。
About BCS Financial: BCS Financial Corporation has more than 70 years of experience delivering a wide-range of insurance and financial solutions for Blue Cross and Blue Shield organizations and commercial markets nationwide. Through its subsidiaries, BCS Insurance Company and 4 Ever Life Insurance Company, BCS is licensed in all 50 states and is rated A (Excellent) by A.M. Best. BCS Financial is headquartered in Oakbrook Terrace, Ill. Learn more at bcsf.com.
关于BCS Financial：BCS金融公司拥有超过70年的经验，为蓝十字会和商业市场提供各种保险和金融解决方案。通过其子公司BCS保险公司和4 Ever人寿保险公司，BCS在所有50个州都有执照，并获得了A.m.最佳的“A（优秀）”评级。BCS金融总部位于伊利诺伊州奥克布鲁克露台。欲知更多信息，请访问bcsf.com。
Media Contact:
Nathan Post
Phone: 630.472.7860.
媒体联系人：
纳森发帖
电话：630.472.7860。
SOURCE BCS Financial
来源BCS Financial
